Welcome to our dedicated page for Tg Therapeutics SEC filings (Ticker: TGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TG Therapeutics' SEC filings document a commercial-stage biotechnology issuer whose common stock trades on the Nasdaq Capital Market under TGTX. The filings cover operating results and financial condition, BRIUMVI product revenue and revenue guidance, license, royalty and other commercialization revenue, and research and development spending tied to its B-cell disease pipeline.
Material-event filings also record capital-structure actions such as senior secured credit financing, repayment of prior term loans, and related borrowing terms. Proxy materials disclose board elections, executive compensation, equity awards, shareholder voting matters, and governance practices for the public company.
TG Therapeutics, Inc. (TGTX) filed a Form S-3 shelf registration as a well-known seasoned issuer on August 8, 2025, providing a framework to offer common stock, preferred stock, warrants, debt securities and units from time to time. The prospectus states proceeds will be used for general corporate purposes and that specific terms will be supplied in prospectus supplements. The company describes itself as a commercial-stage biopharmaceutical firm with FDA approval of BRIUMVI (ublituximab-xiiy) for relapsing forms of multiple sclerosis and parallel approvals in the EU and the UK.
The prospectus discloses 158,665,613 shares outstanding as of August 5, 2025 and approximately 199 holders of record, authorized common stock of 190,000,000 shares, and authorized preferred stock of 10,000,000 shares (none outstanding). The registrant notes the Nasdaq symbol "TGTX" and a closing price of $27.70 per share on August 6, 2025. The document incorporates prior reports including the 2024 Form 10-K and 2025 Form 10-Q filings and highlights extensive forward-looking risk factors that investors should review.
TG Therapeutics reported strong year-over-year commercial progress driven by BRIUMVI sales and improved profitability. For the six months ended June 30, 2025 the company recognized $262.0 million of total revenue, primarily product revenue from U.S. BRIUMVI sales, compared with $136.9 million in the prior-year period. GAAP net income was $33.2 million for the six months and $28.2 million for the quarter, reversing prior-year losses.
The balance sheet shows current assets of $663.96 million including cash, cash equivalents and investment securities the company states as $278.9 million available with management anticipating liquidity for more than twelve months. Working capital increased: accounts receivable rose to $231.5 million and inventory to $155.2 million. The company has a secured term loan with a carrying amount of $245.0 million (non-current) and an accumulated deficit of approximately $1.5 billion. Results reflect ongoing commercialization of BRIUMVI and related license revenue from ex-U.S. partner Neuraxpharm.